FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033896333> ?p ?o ?g. }

• W2033896333 endingPage "798" @default.
• W2033896333 startingPage "785" @default.
• W2033896333 abstract "Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population. Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population." @default.
• W2033896333 created "2016-06-24" @default.
• W2033896333 creator A5018961761 @default.
• W2033896333 creator A5047313234 @default.
• W2033896333 creator A5060050314 @default.
• W2033896333 creator A5074587712 @default.
• W2033896333 creator A5084375517 @default.
• W2033896333 creator A5088002863 @default.
• W2033896333 date "2015-05-01" @default.
• W2033896333 modified "2023-10-14" @default.
• W2033896333 title "Niacin and Progression of CKD" @default.
• W2033896333 cites W1512580963 @default.
• W2033896333 cites W1549645780 @default.
• W2033896333 cites W1738546326 @default.
• W2033896333 cites W1790120012 @default.
• W2033896333 cites W1856460279 @default.
• W2033896333 cites W1859162852 @default.
• W2033896333 cites W1963912836 @default.
• W2033896333 cites W1964534176 @default.
• W2033896333 cites W1968640167 @default.
• W2033896333 cites W1969735455 @default.
• W2033896333 cites W1969782978 @default.
• W2033896333 cites W1971213885 @default.
• W2033896333 cites W1971670881 @default.
• W2033896333 cites W1971912406 @default.
• W2033896333 cites W1975380802 @default.
• W2033896333 cites W1978500134 @default.
• W2033896333 cites W1980316499 @default.
• W2033896333 cites W1980946271 @default.
• W2033896333 cites W1981633985 @default.
• W2033896333 cites W1982351423 @default.
• W2033896333 cites W1989608414 @default.
• W2033896333 cites W1994712431 @default.
• W2033896333 cites W1995587396 @default.
• W2033896333 cites W1996629841 @default.
• W2033896333 cites W1996978408 @default.
• W2033896333 cites W2000103162 @default.
• W2033896333 cites W2002720021 @default.
• W2033896333 cites W2005184654 @default.
• W2033896333 cites W2012766272 @default.
• W2033896333 cites W2015438325 @default.
• W2033896333 cites W2015708524 @default.
• W2033896333 cites W2016045645 @default.
• W2033896333 cites W2019156975 @default.
• W2033896333 cites W2020338109 @default.
• W2033896333 cites W2022162088 @default.
• W2033896333 cites W2023130651 @default.
• W2033896333 cites W2025542180 @default.
• W2033896333 cites W2026165785 @default.
• W2033896333 cites W2026353630 @default.
• W2033896333 cites W2029833995 @default.
• W2033896333 cites W2030059148 @default.
• W2033896333 cites W2033862533 @default.
• W2033896333 cites W2040477702 @default.
• W2033896333 cites W2041759226 @default.
• W2033896333 cites W2044507358 @default.
• W2033896333 cites W2044574640 @default.
• W2033896333 cites W2044628808 @default.
• W2033896333 cites W2046991199 @default.
• W2033896333 cites W2047680488 @default.
• W2033896333 cites W2048395695 @default.
• W2033896333 cites W2048760408 @default.
• W2033896333 cites W2051240093 @default.
• W2033896333 cites W2055801973 @default.
• W2033896333 cites W2056542784 @default.
• W2033896333 cites W2056916232 @default.
• W2033896333 cites W2067955790 @default.
• W2033896333 cites W2068797907 @default.
• W2033896333 cites W2069131327 @default.
• W2033896333 cites W2070739410 @default.
• W2033896333 cites W2070999659 @default.
• W2033896333 cites W2071386184 @default.
• W2033896333 cites W2072225877 @default.
• W2033896333 cites W2072836564 @default.
• W2033896333 cites W2072933848 @default.
• W2033896333 cites W2075391935 @default.
• W2033896333 cites W2078344866 @default.
• W2033896333 cites W2078465235 @default.
• W2033896333 cites W2078578691 @default.
• W2033896333 cites W2078631776 @default.
• W2033896333 cites W2080258689 @default.
• W2033896333 cites W2080449100 @default.
• W2033896333 cites W2083522786 @default.
• W2033896333 cites W2084923022 @default.
• W2033896333 cites W2085625674 @default.
• W2033896333 cites W2089756265 @default.
• W2033896333 cites W2091399276 @default.
• W2033896333 cites W2094306661 @default.
• W2033896333 cites W2096796626 @default.
• W2033896333 cites W2098566970 @default.
• W2033896333 cites W2098795260 @default.
• W2033896333 cites W2098796476 @default.
• W2033896333 cites W2101164884 @default.
• W2033896333 cites W2101969945 @default.
• W2033896333 cites W2102734552 @default.
• W2033896333 cites W2102873572 @default.
• W2033896333 cites W2103393658 @default.
• W2033896333 cites W2105868148 @default.

• next